Notice: This company has been marked as potentially delisted and may not be actively trading. Opiant Pharmaceuticals (OPNT) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Movers From YesterdayOctober 10, 2024 | benzinga.comCNFinance Hldgs (NYSE:CNF) Stock Quotes, Forecast and News SummaryOctober 8, 2024 | benzinga.comHikma Pharmaceuticals PLC ADR (HKMPY)April 18, 2024 | investing.comIonis PharmaceuticalsJanuary 31, 2024 | forbes.comUPDATE 2-US FDA approves Opiant's spray for reversing opioid-related overdosesMay 24, 2023 | msn.comREFILE-US FDA approves Opiant's overdose reversal sprayMay 23, 2023 | msn.comIndivior Acquires Opiant Pharmaceuticals Strengthening Its Addiction Treatment And Science PortfolioMarch 3, 2023 | msn.comTrading was temporarily halted for "OPNT" at 07:03 PM with a stated reason of "News pending."March 2, 2023 | marketbeat.comOpiant Pharmaceuticals, Inc.'s (NASDAQ:OPNT) largest shareholders are individual investors with 52% ownership, institutions own 33%February 22, 2023 | finance.yahoo.comOpiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLCFebruary 7, 2023 | finance.yahoo.comHorizon Pharma, Opiant fall amid Elizabeth Warren concern about pharma deals (update)January 26, 2023 | seekingalpha.comOpiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid OverdoseJanuary 19, 2023 | finance.yahoo.comDechra Pharmaceuticals defies cooling pets marketJanuary 14, 2023 | thetimes.co.ukOpiant Pharmaceuticals: Nano-Cap Buyout With Interesting CVR Thrown InJanuary 13, 2023 | seekingalpha.comOpiant Pharmaceuticals, Inc. (NASDAQ:OPNT) CEO Sells $23,896.60 in StockOpiant Pharmaceuticals, Inc. (NASDAQ:OPNT - Get Rating) CEO Roger Crystal sold 1,183 shares of the stock in a transaction on Monday, January 9th. The stock was sold at an average price of $20.20, for a total transaction of $23,896.60. Following the completion of the transaction, the chief executive officer now directly owns 76,697 shares in the company, valued at approximately $1,549,279.40. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.January 9, 2023 | marketbeat.comOPIANT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Opiant ...January 7, 2023 | businesswire.comOpiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Short Interest UpdateOpiant Pharmaceuticals, Inc. (NASDAQ:OPNT - Get Rating) was the recipient of a significant increase in short interest in the month of December. As of December 15th, there was short interest totalling 30,700 shares, an increase of 153.7% from the November 30th total of 12,100 shares. Based on an average daily trading volume, of 85,100 shares, the days-to-cover ratio is presently 0.4 days.December 28, 2022 | marketbeat.comOpiant Pharmaceuticals (NASDAQ:OPNT) Cut to "Market Perform" at Northland SecuritiesNorthland Securities lowered shares of Opiant Pharmaceuticals from an "outperform" rating to a "market perform" rating in a report on Wednesday.November 23, 2022 | marketbeat.comOpiant Pharmaceuticals Announces Completion of Rolling NDA Submission for OPNT003, Nasal Nalmefene, for Opioid OverdoseNovember 22, 2022 | finance.yahoo.comOppenheimer Comments on Opiant Pharmaceuticals, Inc.'s FY2022 Earnings (NASDAQ:OPNT)Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT - Get Rating) - Investment analysts at Oppenheimer reduced their FY2022 earnings per share estimates for Opiant Pharmaceuticals in a report released on Monday, November 14th. Oppenheimer analyst L. Gershell now expects that the technology company will earNovember 17, 2022 | marketbeat.comOPNT Alert: Monsey Firm of Wohl & Fruchter LLP Investigating Sale of Opiant PharmaceuticalsNovember 15, 2022 | benzinga.comEQUITY ALERT: The M&A Class Action Firm Announces the Investigation of Opiant Pharmaceuticals, Inc. - OPNTNovember 15, 2022 | benzinga.comShareholder Alert: Ademi LLP investigates whether Opiant Pharmaceuticals Inc. has obtained a Fair Price in its transaction with IndiviorNovember 14, 2022 | benzinga.comOPNT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Opiant Pharmaceuticals, Inc. Is Fair to ShareholdersNovember 14, 2022 | benzinga.comIndivior To Buy Opiant For $145 Mln In CashNovember 14, 2022 | nasdaq.comOpiant surges 123% as Indivior set to acquire overdose therapy maker for $145MNovember 14, 2022 | seekingalpha.comOpiant Pharmaceuticals Shares Surge Premarket on Takeover by Indivior >OPNTNovember 14, 2022 | marketwatch.comIndivior PLC to Acquire Opiant PharmaceuticalsNovember 14, 2022 | finance.yahoo.comOpiant Pharmaceuticals Announces Third Quarter 2022 Financial ResultsNovember 14, 2022 | finance.yahoo.comNarcan Owner Opiant to Be Acquired by Indivior for $145 MillionNovember 14, 2022 | finance.yahoo.comThe past five years for Opiant Pharmaceuticals (NASDAQ:OPNT) investors has not been profitableNovember 2, 2022 | finance.yahoo.comOpiant Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 14, 2022October 27, 2022 | finance.yahoo.comOpiant Pharmaceuticals Announces Completion of Enrollment in Phase 2 Clinical Trial of OPNT002, Nasal Naltrexone, in Patients with Alcohol Use DisorderOctober 6, 2022 | finance.yahoo.comINVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Opiant Pharmaceuticals, Inc. for Potential Breach of Fiduciary Duty ClaimsOctober 5, 2022 | marketwatch.comOpiant Pharmaceuticals Announces Notice of Allowance for U.S. Patent with Claims Covering OPNT004 for the Treatment of Cannabinoid Hyperemesis SyndromeAugust 22, 2022 | finance.yahoo.comAnalysts Just Shaved Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Forecasts DramaticallyAugust 13, 2022 | finance.yahoo.comOpiant Pharmaceuticals Announces Second Quarter and First Half 2022 Financial Results and Provides Corporate UpdateAugust 11, 2022 | finance.yahoo.comOpiant Pharma Secures Additional BARDA Funding For Opioid Overdose TreatmentAugust 9, 2022 | finance.yahoo.comOpiant Pharmaceuticals Announces Additional $2.1 Million Funding Under BARDA Contract for OPNT003, Nasal NalmefeneAugust 8, 2022 | finance.yahoo.comOpiant Pharmaceuticals, Inc. (NASDAQ:OPNT) insiders sold US$871k worth of stock, possibly signalling a downtrendAugust 4, 2022 | nasdaq.comOpiant Pharmaceuticals Announces Notice of Allowance for U.S. Patent With Claims Covering OPNT003 for the Treatment of Opioid OverdoseAugust 2, 2022 | finance.yahoo.comOpiant Pharmaceuticals to Report Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11, 2022August 1, 2022 | finance.yahoo.comA Look At The Fair Value Of Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT)June 9, 2022 | finance.yahoo.comOpiant Pharmaceuticals and Aptar Pharma Expand Long-Term Collaboration for the Manufacture of Unidose Nasal Spray for OPNT003, Nasal NalmefeneJune 8, 2022 | finance.yahoo.comOpiant Pharmaceuticals Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for OPNT003, Nasal Nalmefene, for the Treatment of Opioid OverdoseJune 1, 2022 | finance.yahoo.comOpiant Pharmaceuticals to Hold Virtual 2022 Annual Shareholder Meeting on Tuesday, June 14, 2022 at 9:00am PDTMay 20, 2022 | finance.yahoo.comOpiant Pharmaceuticals, Inc. (OPNT) CEO Dr. Roger Crystal on Q1 2022 Results - Earnings Call TranscriptMay 14, 2022 | seekingalpha.comTrading was temporarily halted for "OPNT" at 09:05 AM with a stated reason of "LULD pause."May 13, 2022 | marketbeat.comTrading was temporarily halted for "OPNT" at 09:05 AM with a stated reason of "LULD pause."May 13, 2022 | marketbeat.comOPNT: Positive Results for Pharmacodynamic Trial of OPNT003…May 12, 2022 | finance.yahoo.com Get Opiant Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for OPNT and its competitors with MarketBeat's FREE daily newsletter. Email Address 2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months. 👉[Click here to get your FREE report delivered instantly!] OPNT Media Mentions By Week OPNT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OPNT News Sentiment▼0.000.46▲Average Medical News Sentiment OPNT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OPNT Articles This Week▼00▲OPNT Articles Average Week Get Opiant Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for OPNT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Foghorn Therapeutics News Rigel Pharmaceuticals News Tango Therapeutics News Verve Therapeutics News Larimar Therapeutics News Akebia Therapeutics News Revance Therapeutics News KalVista Pharmaceuticals News Amylyx Pharmaceuticals News XOMA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OPNT) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opiant Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Opiant Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
